Study Summary
This trial is testing a new cancer drug to see what dose is safe and how it affects people with advanced solid tumors.
- Solid Tumors, Adult
Treatment Effectiveness
Study Objectives
2 Primary · 7 Secondary · Reporting Duration: Approximately 2.5 years
Trial Safety
Awards & Highlights
Trial Design
1 Treatment Group
JAB-8263
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: JAB-8263 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How does this experiment strive to improve patient outcomes?
"This trial, which is slated to last for two-and-a-half years, seeks to identify the appropriate dosage of JAB-8263. Secondary aims include assessing duration of response (DOR), peak plasma concentration (Cmax) and adverse events associated with treatment." - Anonymous Online Contributor
What is the target enrollment size of this experiment?
"Jacobio Pharmaceuticals Co., Ltd. is the sponsor responsible for running this trial, which requires 30 participants who meet its inclusion criteria. The two primary sites are Tennessee Oncology Nashville in Nashville, Tennessee and SCRI HealthONE in Denver, Colorado." - Anonymous Online Contributor
Is the recruitment period open for this experiment?
"On clinicaltrials.gov, the data confirms that enrollment is still open for this study which was first launched on November 23rd 2020 and recently revised on March 11th 2022." - Anonymous Online Contributor
Has the regulatory body authorized JAB-8263 for public use?
"Based on the data currently available, JAB-8263 has been provisionally assigned a safety rating of 1 due to its current stage in clinical trials. At this point, there is minimal evidence for both efficacy and safety." - Anonymous Online Contributor